ASSOCIATION OF ANTI-FIBRILLARIN ANTIBODIES WITH SKIN FIBROSIS IN SYSTEMIC SCLEROSIS
Keywords:
To evaluate the clinical significance of anti-fibrillarin antibodies in patients with systemic sclerosis, with particular emphasis on the severity of skin fibrosis.Abstract
Antinuclear antibodies (ANA) represent a heterogeneous group of autoantibodies that play a central role in the immunopathogenesis of systemic sclerosis. Different ANA specificities are associated with distinct clinical phenotypes, disease progression patterns, and degrees of skin and internal organ involvement. Evaluation of specific ANA subsets may therefore provide important prognostic information, particularly with regard to the severity of skin fibrosis and systemic manifestations.
Downloads
References
Beringer, A., & Miossec, P. (2019). Systemic effects of IL-17 in inflammatory arthritis. Nature Reviews Rheumatology, 15(8), 491-501.
Kunwar, S., Dahal, K., & Sharma, S. (2016). Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology international, 36(8), 1065-1075.
Miossec, P. (2021). Local and systemic effects of IL-17 in joint inflammation: a historical perspective from discovery to targeting. Cellular & Molecular Immunology, 18(4), 860-865.
Zhang, X., Yuan, Y., Pan, Z., Ma, Y., Wu, M., Yang, J., ... & Pan, F. (2019). Elevated circulating IL-17 level is associated with inflammatory arthritis and disease activity: A meta-analysis. Clinica Chimica Acta, 496, 76-83.
